| Literature DB >> 29743556 |
Judyta Nowak1, Bogusław Pawłowski2, Barbara Borkowska2, Daria Augustyniak3, Zuzanna Drulis-Kawa3.
Abstract
The observations that testosterone might be immunosuppressive, form the basis for the immunocompetence handicap hypothesis (ICHH). According to ICHH only high-quality individuals can maintain high levels of testosterone and afford the physiological cost of hormone-derived immunosuppression. The animal and human studies that attempted to support the ICHH by precisely defined impairment of immunity associated with high testosterone levels are inconclusive. Furthermore, human studies have used only selected immune functions and varying testosterone fractions. This is the first study examining the relationship between multiple innate and adaptive immunity and serum levels of free testosterone, total testosterone, DHT and DHEA in ninety-seven healthy men. Free testosterone and marginally DHT levels were positively correlated with the strength of the influenza post-vaccination response. Total testosterone and DHEA showed no immunomodulatory properties. Our findings did not support ICHH assumptions about immunosuppressive function of androgens. In the affluent society studied here, men with higher levels of free testosterone could afford to invest more in adaptive immunity. Since the hormone-immune relationship is complex and may depend on multiple factors, including access to food resources, androgens should be treated as immunomodulators rather than implicit immunosuppressants.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29743556 PMCID: PMC5943526 DOI: 10.1038/s41598-018-25694-0
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Descriptive statistics for the analyzed parameters (N = 97).
| Mean | Range | SD | |
|---|---|---|---|
|
| 27.2 | 18.97–36.7 | 4.77 |
|
| 179.87 | 47.14–287.53 | 58.01 |
|
| 0.4 | 0.08–0.6 | 0.08 |
|
| 174.7 | 54.30–429.9 | 64.28 |
|
| 9.0 | 2.47–60.1 | 9.21 |
|
| 1.9 | 0.57–7.3 | 1.10 |
|
| 12.0 | 4.16–27.0 | 4.29 |
| 1515.8 | 538.13–3422.8 | 536.46 | |
| 246.3 | 45.33–639.9 | 119.71 | |
|
| 8.2 | 1.00–64.0 | 9.73 |
|
| 8.2 | 0.69–45.7 | 9.46 |
|
| 99.8 | 7.64–324.8 | 51.83 |
|
| 36.1 | 9.15–106.2 | 18.46 |
|
| 23.7 | 2.53–52.6 | 9.91 |
|
| 5.4 | 1.91–8.4 | 1.11 |
|
| 15.6 | 2.79–33.9 | 6.17 |
|
| 719.0 | 364.35–1061.8 | 128.24 |
| 23.7 | 16.87–29.9 | 2.85 | |
|
| 20.8 | 7.20–32.5 | 4.80 |
1The difference in absorbance value between control samples (bacteria suspension without lysozyme) and test samples (bacteria treated with serum-contained lysozymes).
2Mean fluorescence intensity of blood phagocytes after phagocytosis of fluorescently labeled bacteria.
3Mean area under the chemiluminescence curve (AUCCL) for stimulated test sample divided by AUCCL for control.
4Fold increase in antibody titers (for influenza) or antibody levels (for tetanus) before and after vaccination.
5Stimulation index − (CPM for stimulated test sample divided by CPM for unstimulated control).
Correlations between immune function parameters and participants’ age, adiposity, and hormone levels.
| Age | BMI | %BF | fT | T | DHEA | DHT | |
|---|---|---|---|---|---|---|---|
| complement activity | 0.023 | 0.019 | 0.131 | −0.002 | 0.193 | 0.040 | 0.064 |
| lysozyme activity | −0.103 | −0.153 | −0.005 | 0.116 | 0.006 | 0.062 | 0.061 |
| phagocytic uptake | 0.010 | 0.170 | −0.015 | −0.150 | −0.009 | −0.004 | −0.114 |
| ROS production | 0.033 | 0.118 | 0.037 | 0.103 | 0.050 | 0.050 | 0.221* |
| IgA level | 0.189 | 0.096 | 0.035 | 0.051 | −0.042 | 0.004 | −0.050 |
| IgG level | −0.148 | −0.112 | −0.115 | 0.052 | 0.118 | 0.002 | 0.217* |
| T lymphocyte count | −0.243* | −0.040 | 0.077 | 0.075 | −0.023 | 0.050 | 0.053 |
| B lymphocyte count | −0.126 | 0.100 | −0.051 | −0.078 | −0.072 | 0.072 | 0.020 |
| strength of flu post-vaccination response | −0.258* | −0.172 | 0.054 | 0.343** | 0.045 | 0.097 | 0.253* |
| strength of tetanus post-vaccination response (N = 35) | 0.209 | 0.109 | 0.096 | 0.271 | 0.286 | 0.136 | 0.186 |
| Proliferation rate after Con A stimulation (N = 62) | −0.204 | 0.044 | 0.069 | 0.169 | −0.059 | 0.046 | 0.051 |
| Proliferation rate after PWM stimulation (N = 62) | −0.103 | 0.129 | 0.092 | 0.218 | −0.078 | 0.062 | 0.098 |
*p < 0.05; **p < 0.001.
Multiple regression models showing the relationship between each androgen and innate immune parameters (a–d), when participants’ age and body mass index (BMI) were controlled.
| Innate immunity parameters | ||||
|---|---|---|---|---|
| Model no 1 | Model no 2 | Model no 3 | Model no 4 | |
|
|
| |||
| fT | −0.022 (0.84) | |||
|
| 0.156 (0.14) | |||
|
| 0.146 (0.18) | |||
|
| 0.162 (0.14) | |||
|
| 0.038 (0.75) | 0.082 (0.47) | 0.096 (0.41) | 0.110 (0.36) |
|
| 0.054 (0.64) | 0.035 (0.75) | 0.029 (0.79) | 0.014 (0.90) |
|
| <0.001 | <0.001 | <0.001 | <0.001 |
|
| <0.89 | <0.42 | <0.49 | <0.43 |
|
|
| |||
| fT | 0.113 (0.30) | |||
|
| 0.020 (0.85) | |||
|
| 0.161 (0.13) | |||
|
| 0.070 (0.52) | |||
|
| −0.050 (0.67) | −0.087 (0.44) | −0.037 (0.75) | −0.064 (0.59) |
|
| −0.138 (0.22) | −0.119 (0.29) | −0.140 (0.21) | −0.133 (0.24) |
|
| 0.011 | <0.001 | 0.023 | 0.004 |
|
| <0.26 | <0.40 | <0.16 | <0.34 |
|
|
| |||
| fT | −0.202 (0.06) | |||
|
| 0.018 (0.86) | |||
|
| −0.164 (0.13) | |||
|
| −0.176 (0.11) | |||
|
| −0.063 (0.59) | 0.017 (0.88) | −0.043 (0.71) | −0.056 (0.64) |
|
| 0.105 (0.35) | 0.066 (0.56) | 0.091 (0.41) | 0.107 (0.34) |
|
| 0.010 0.002* | <0.001 | <0.001 | 0.001 |
|
| <0.26 | <0.91 | <0.42 | <0.38 |
|
|
| |||
| fT | 0.061 (0.57) | |||
|
| 0.001 (0.99) | |||
|
| 0.072 (0.50) | |||
|
| 0.198 (0.07) | |||
|
| −0.029 (0.81) | −0.052 (0.65) | −0.027 (0.81) | 0.026 (0.82) |
|
| 0.169 (0.14) | 0.180 (0.11) | 0.169 (0.13) | 0.136 (0.23) |
|
| <0.001 | <0.001 | 0.001 | 0.031 |
|
| <0.40 | <0.45 | <0.38 | <0.11 |
*Standardized beta coefficients with p values in parentheses for analyses without statistical outliers for immune factors (N = 93 for phagocytic uptake, and N = 94 for reactive oxygen species [ROS] production).
Entries are standardized beta coefficients with p values in parentheses.
Multiple regression models showing the relationship between each androgen and adaptive immune parameters (a–g), when participants’ age and body mass index (BMI) were controlled.
| Adaptive immunity parameters | ||||
|---|---|---|---|---|
| Model no 1 | Model no 2 | Model no 3 | Model no 4 | |
|
|
| |||
| fT | 0.125 (0.24) | |||
|
| 0.010 (0.92) | |||
|
| 0.055 (0.61) | |||
|
| 0.079 (0.47) | |||
|
| ||||
|
| −0.010 (0.92) | 0.011 (0.91) | 0.005 (0.97) | −0.005 (0.96) |
|
| 0.03 | 0.02 | 0.02 | 0.02 |
|
| <0.10 | <0.18 | <0.16 | <0.14 |
|
|
| |||
| fT | 0.051 (0.64) | |||
|
| 0.118 (0.26) | |||
|
| 0.004 (0.96) | |||
|
| 0.184 (0.09) | |||
|
| −0.114 (0.33) | −0.106 (0.34) | −0.132 (0.26) | −0.061 (0.60) |
|
| −0.101 (0.37) | −0.102 (0.35) | −0.092 (0.41) | −0.132 (0.24) |
|
| 0.007 | 0.018 | 0.004 | 0.035 |
|
| <0.30 | <0.19 | <0.33 | <0.10 |
|
| ||||
| fT | −0.009 (0.93) | |||
|
| −0.065 (0.53) | |||
|
| 0.027 (0.80) | |||
|
| −0.047 (0.66) | |||
|
| ||||
|
| 0.051 (0.64) | 0.056 (0.61) | 0.046 (0.67) | 0.060 (0.59) |
|
| 0.042 | 0.047 | 0.043 | 0.045 |
|
| <0.07 | <0.06 | <0.07 | <0.06 |
|
| ||||
| fT | −0.160 (0.14) | |||
|
| −0.140 (0.18) | |||
|
| −0.051 (0.63) | |||
|
| −0.077 (. 48) | |||
|
| −0.212 (0.06) | −0.197 (0.09) | −0.210 (0.08) | |
|
| 0.109 (0.33) | 0.094 (0.40) | 0.087 (0.43) | 0.097 (0.39) |
|
| 0.019 | 0.015 | <0.001 | 0.001 |
|
| <0.19 | <0.22 | <0.42 | <0.37 |
|
|
| |||
| fT | ||||
|
| 0.001 (0.99) | |||
|
| 0.080 (0.44) | |||
|
| 0.197 | |||
|
| −0.179 (0.11) | −0.183 (0.10) | ||
|
| −0.077 (0.47) | −0.035 (0.74) | −0.046 (0.67) | −0.079 (0.47) |
|
| 0.098 | 0.049 | 0.055 | 0.084 |
|
| <0.005 | <0.05 | <0.04 | <0.01 |
|
| ||||
| fT | 0.018 (0.90) | |||
|
| −0.054 (0.69) | |||
|
| −0.081 (0.55) | |||
|
| −0.030 (0.82) | |||
|
| −0.195 (0.20) | −0.219 (0.14) | −0.229 (0.12) | −0.212 (0.16) |
|
| 0.106 (0.46) | 0.118 (0.41) | 0.124 (0.38) | 0.116 (0.42) |
|
| <0.001 | <0.001 | <0.001 | <0.001 |
|
| <0.55 | <0.52 | <0.48 | <0.54 |
|
| ||||
| fT | 0.019 (0.89) | |||
|
| −0.154 (0.26) | |||
|
| −0.134 (0.33) | |||
|
| −0.016 (0.91) | |||
|
| −0.145 (0.34) | −0.203 (0.17) | −0.198 (0.18) | −0.158 (0.29) |
|
| 0.069 (0.63) | 0.100 (0.48) | 0.098 (0.49) | 0.076 (0.60) |
|
| <0.001 | <0.001 | <0.001 | <0.001 |
|
| <0.75 | <0.48 | <0.54 | <0.76 |
Entries are standardized beta coefficients with p values in parentheses.